Strategies to Accelerate the Development of Antibody-Drug Conjugates
Antibody-drug conjugates (ADCs) hold great promise as cancer therapeutics, as they combine the precision of monoclonal antibodies with the potency of cytotoxic drugs. This type of targeted delivery can minimize harm to healthy tissues, reducing side effects and potentially improving the therapeutic window. However, the complex structure of ADCs poses significant development and safety challenges for project teams.
In our latest White Paper, we share essential strategies for accelerating the development of ADCs, with special consideration given to ADC design, resistance mechanisms, safety assessment, and PK/PD studies.
ADC White Paper_WuXi AppTec
Related Content
Antibody-drug conjugates (ADCs) are increasingly demonstrating their value in cancer treatment, especially in combination therapies and for targeting resistant cancer...
VIEW RESOURCEAntibody-Drug Conjugates (ADCs) have made significant advancements in cancer treatment, particularly for solid tumors. The bystander effect of ADCs, where...
VIEW RESOURCE